These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20372080)

  • 1. Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.
    Petrovic V; Costa RH; Lau LF; Raychaudhuri P; Tyner AL
    Cancer Biol Ther; 2010 Jun; 9(12):1008-16. PubMed ID: 20372080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sp1 mediates repression of the resistin gene by PPARgamma agonists in 3T3-L1 adipocytes.
    Chung SS; Choi HH; Cho YM; Lee HK; Park KS
    Biochem Biophys Res Commun; 2006 Sep; 348(1):253-8. PubMed ID: 16876120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
    Tsujie M; Nakamori S; Okami J; Hayashi N; Hiraoka N; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Exp Cell Res; 2003 Sep; 289(1):143-51. PubMed ID: 12941612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
    Tabatabaei Dakhili SA; Pérez DJ; Gopal K; Haque M; Ussher JR; Kashfi K; Velázquez-Martínez CA
    Eur J Med Chem; 2021 Jan; 209():112902. PubMed ID: 33069434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
    Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
    Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
    Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
    Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
    Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
    Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.
    Kong X; Li L; Li Z; Le X; Huang C; Jia Z; Cui J; Huang S; Wang L; Xie K
    Cancer Res; 2013 Jul; 73(13):3987-96. PubMed ID: 23598278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1.
    Baek SJ; Kim JS; Nixon JB; DiAugustine RP; Eling TE
    J Biol Chem; 2004 Feb; 279(8):6883-92. PubMed ID: 14662774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells.
    Toyoda M; Takagi H; Horiguchi N; Kakizaki S; Sato K; Takayama H; Mori M
    Gut; 2002 Apr; 50(4):563-7. PubMed ID: 11889080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition of pancreatic cancer cells through activation of peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
    Tsujie M; Nakamori S; Okami J; Takahashi Y; Hayashi N; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Int J Oncol; 2003 Aug; 23(2):325-31. PubMed ID: 12851681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unliganded RXR acts as an inhibitory factor on troglitazone-induced activation.
    Monden T; Yamada M; Nihei Y; Kishi M; Tomaru T; Ishii S; Hashida T; Shibusawa N; Hashimoto K; Satoh T; Kasai K; Mori M
    Life Sci; 2004 Dec; 76(7):731-41. PubMed ID: 15581905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells.
    Coyle AT; Kinsella BT
    Biochem Pharmacol; 2006 Apr; 71(9):1308-23. PubMed ID: 16499875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1.
    Deng T; Shan S; Li PP; Shen ZF; Lu XP; Cheng J; Ning ZQ
    Endocrinology; 2006 Feb; 147(2):875-84. PubMed ID: 16269451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human scavenger receptor class B type 1 is regulated by activators of peroxisome proliferators-activated receptor-gamma in hepatocytes.
    Ahmed RA; Murao K; Imachi H; Yu X; Li J; Wong NC; Ishida T
    Endocrine; 2009 Apr; 35(2):233-42. PubMed ID: 19156545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.
    Pseftogas A; Gonidas C; Mosialos G
    Int J Biochem Cell Biol; 2017 Jan; 82():49-56. PubMed ID: 27865894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism.
    Davies GF; Khandelwal RL; Wu L; Juurlink BH; Roesler WJ
    Biochem Pharmacol; 2001 Oct; 62(8):1071-9. PubMed ID: 11597575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists.
    Costa V; Foti D; Paonessa F; Chiefari E; Palaia L; Brunetti G; Gulletta E; Fusco A; Brunetti A
    Endocr Relat Cancer; 2008 Mar; 15(1):325-35. PubMed ID: 18310298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1.
    Gao M; Hu Z; Zheng Y; Zeng Y; Shen X; Zhong D; He F
    Shock; 2011 Sep; 36(3):228-34. PubMed ID: 21617575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
    Bonofiglio D; Qi H; Gabriele S; Catalano S; Aquila S; Belmonte M; Andò S
    Endocr Relat Cancer; 2008 Jun; 15(2):545-57. PubMed ID: 18509005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.